New pill combo aims to tackle Hard-to-Treat colorectal cancer
NCT ID NCT07391566
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new oral drug, LPM6690176, added to standard chemotherapy and bevacizumab for people with a specific type of advanced colorectal cancer (RAS mutation). The first part finds the safest dose, and the second part compares the new combo against standard treatment alone. About 99 adults who have not had prior therapy for metastatic disease will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LPM6690176 capsules combined with chemotherapy (FOLFIRI) and bevacizumab
What this could lead to
If successful, this could offer a new first-line treatment option for people with RAS-mutant metastatic colorectal cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is an early-phase trial (Phase 1b/2) with only 99 participants, so safety and effectiveness are not yet proven. The drug combination may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••